Published in Am J Pathol on April 01, 2009
Function, regulation and pathological roles of the Gab/DOS docking proteins. Cell Commun Signal (2009) 1.59
Reverse-phase protein array analysis to identify biomarker proteins in human pancreatic cancer. Dig Dis Sci (2013) 1.43
Gab2 regulates the migratory behaviors and E-cadherin expression via activation of the PI3K pathway in ovarian cancer cells. Oncogene (2011) 1.11
GAB2--a scaffolding protein in cancer. Mol Cancer Res (2012) 1.09
Survivin enhances motility of melanoma cells by supporting Akt activation and {alpha}5 integrin upregulation. Cancer Res (2010) 1.06
In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene. Proc Natl Acad Sci U S A (2014) 0.99
GAB2 amplifications refine molecular classification of melanoma. Clin Cancer Res (2009) 0.97
Differential volatile signatures from skin, naevi and melanoma: a novel approach to detect a pathological process. PLoS One (2010) 0.97
Gab2 facilitates epithelial-to-mesenchymal transition via the MEK/ERK/MMP signaling in colorectal cancer. J Exp Clin Cancer Res (2016) 0.92
The signaling adaptor GAB1 regulates cell polarity by acting as a PAR protein scaffold. Mol Cell (2012) 0.91
GAB2 induces tumor angiogenesis in NRAS-driven melanoma. Oncogene (2012) 0.89
C-KIT signaling depends on microphthalmia-associated transcription factor for effects on cell proliferation. PLoS One (2011) 0.88
RUNX2 and the PI3K/AKT axis reciprocal activation as a driving force for tumor progression. Mol Cancer (2015) 0.87
Gab2 regulates cytoskeletal organization and migration of mammary epithelial cells by modulating RhoA activation. Mol Biol Cell (2010) 0.87
Gab docking proteins in cardiovascular disease, cancer, and inflammation. Int J Inflam (2013) 0.85
Computational Model of Gab1/2-Dependent VEGFR2 Pathway to Akt Activation. PLoS One (2013) 0.84
Overexpression of Grb2-associated binder 2 in human lung cancer. Int J Biol Sci (2011) 0.84
Structure and function of Gab2 and its role in cancer (Review). Mol Med Rep (2015) 0.81
Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1. Blood (2016) 0.80
Gab2 is a novel prognostic factor for colorectal cancer patients. Int J Clin Exp Pathol (2015) 0.80
The transcription factor RUNX2 regulates receptor tyrosine kinase expression in melanoma. Oncotarget (2016) 0.78
A time course-dependent metastatic gene expression signature predicts outcome in human metastatic melanomas. Diagn Pathol (2014) 0.76
K+ Channel Inhibition Differentially Regulates Migration of Intestinal Epithelial Cells in Inflamed vs. Non-Inflamed Conditions in a PI3K/Akt-Mediated Manner. PLoS One (2016) 0.75
Oncogenic Signaling Adaptor Proteins. J Genet Genomics (2015) 0.75
Critical Role for GAB2 in Neuroblastoma Pathogenesis through the Promotion of SHP2/MYCN Cooperation. Cell Rep (2017) 0.75
Cancer statistics, 2006. CA Cancer J Clin (2006) 30.71
The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer (2002) 28.11
Melanoma biology and new targeted therapy. Nature (2007) 10.71
Management of cutaneous melanoma. N Engl J Med (2004) 9.52
Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med (2002) 8.04
Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res (2005) 6.93
A bacterial artificial chromosome library for sequencing the complete human genome. Genome Res (2001) 3.81
Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res (2004) 3.80
The "Gab" in signal transduction. Trends Cell Biol (2003) 2.52
Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell (2002) 2.42
Mitogen-actived protein kinase activation is an early event in melanoma progression. Clin Cancer Res (2002) 2.18
Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res Treat (2003) 2.14
A role for the scaffolding adapter GAB2 in breast cancer. Nat Med (2005) 2.12
PTEN signaling pathways in melanoma. Oncogene (2003) 1.98
The gift of Gab. FEBS Lett (2002) 1.90
Use of human tissue to assess the oncogenic activity of melanoma-associated mutations. Nat Genet (2005) 1.90
Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res (2002) 1.78
Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin. Cancer Res (2000) 1.67
Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment. Br J Dermatol (2007) 1.49
Detailed map of a region commonly amplified at 11q13-->q14 in human breast carcinoma. Cytogenet Cell Genet (1997) 1.48
Coexpression of NRASQ61R and BRAFV600E in human melanoma cells activates senescence and increases susceptibility to cell-mediated cytotoxicity. Cancer Res (2006) 1.43
Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling. J Biol Chem (2004) 1.39
RNA interference inhibition of matrix metalloproteinase-1 prevents melanoma metastasis by reducing tumor collagenase activity and angiogenesis. Cancer Res (2007) 1.39
Suprabasal alpha6beta4 integrin expression in epidermis results in enhanced tumourigenesis and disruption of TGFbeta signalling. J Cell Sci (2003) 1.37
Undifferentiated keratinocytes control growth, morphology, and antigen expression of normal melanocytes through cell-cell contact. Lab Invest (1993) 1.36
Role of Gab2 in mammary tumorigenesis and metastasis. Oncogene (2007) 1.27
The docking protein Gab2 is overexpressed and estrogen regulated in human breast cancer. Oncogene (2002) 1.26
Analysis of ovarian cancer cell lines using array-based comparative genomic hybridization. J Pathol (2005) 1.17
B-RAF regulation of Rnd3 participates in actin cytoskeletal and focal adhesion organization. Mol Biol Cell (2007) 1.15
Challenges in array comparative genomic hybridization for the analysis of cancer samples. Genet Med (2007) 1.14
Optimised retroviral infection of human epidermal keratinocytes: long-term expression of transduced integrin gene following grafting on to SCID mice. Gene Ther (1998) 1.11
PI3 kinase blockade by Ad-PTEN inhibits invasion and induces apoptosis in RGP and metastatic melanoma cells. Mol Med (2002) 1.11
Gab2 and Src co-operate in human mammary epithelial cells to promote growth factor independence and disruption of acinar morphogenesis. Oncogene (2007) 0.99
A gene expression atlas of the central nervous system based on bacterial artificial chromosomes. Nature (2003) 16.48
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell (2011) 11.44
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res (2005) 8.98
Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med (2002) 8.04
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A (2009) 7.95
Recurrent 16p11.2 microdeletions in autism. Hum Mol Genet (2007) 6.75
Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med (2007) 6.55
X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res (2004) 6.22
N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat Chem Biol (2011) 5.96
Exome sequencing-based copy-number variation and loss of heterozygosity detection: ExomeCNV. Bioinformatics (2011) 5.45
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A (2007) 5.44
The New York Cancer Project: rationale, organization, design, and baseline characteristics. J Urban Health (2004) 5.21
Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis. J Clin Oncol (2006) 4.66
The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res (2008) 4.63
Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev (2007) 4.23
Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc Natl Acad Sci U S A (2008) 4.13
Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst (2005) 4.01
Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet (2007) 3.95
Extra-embryonic function of Rb is essential for embryonic development and viability. Nature (2003) 3.92
Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res (2004) 3.64
Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst (2005) 3.62
Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to the recovery from acute kidney injury. Am J Physiol Renal Physiol (2007) 3.54
Gene transfer into genomes of human cells by the sleeping beauty transposon system. Mol Ther (2003) 3.34
Attendance at the accident and emergency department in the year before suicide: retrospective study. Br J Psychiatry (2003) 3.00
Cell type-specific DNA methylation patterns in the human breast. Proc Natl Acad Sci U S A (2008) 2.99
Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell (2005) 2.98
Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol (2009) 2.94
Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci U S A (2002) 2.89
A secreted PTEN phosphatase that enters cells to alter signaling and survival. Science (2013) 2.86
Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. J Clin Oncol (2011) 2.78
GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature (2009) 2.77
Technology insight: Identification of biomarkers with tissue microarray technology. Nat Clin Pract Oncol (2004) 2.74
Is breast cancer survival improving? Cancer (2004) 2.73
PBAF chromatin-remodeling complex requires a novel specificity subunit, BAF200, to regulate expression of selective interferon-responsive genes. Genes Dev (2005) 2.70
PTEN: from pathology to biology. Trends Cell Biol (2003) 2.69
Novel submicroscopic chromosomal abnormalities detected in autism spectrum disorder. Biol Psychiatry (2008) 2.60
Distinct IL-2 receptor signaling pattern in CD4+CD25+ regulatory T cells. J Immunol (2004) 2.54
Activation of the PI3K pathway in cancer through inhibition of PTEN by exchange factor P-REX2a. Science (2009) 2.51
Pax6 is a human neuroectoderm cell fate determinant. Cell Stem Cell (2010) 2.46
Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res (2005) 2.46
Long-term preservation of antigenicity on tissue microarrays. Lab Invest (2004) 2.44
Single-spike detection in vitro and in vivo with a genetic Ca2+ sensor. Nat Methods (2008) 2.44
A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers. J Clin Oncol (2008) 2.43
Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. Proc Natl Acad Sci U S A (2009) 2.41
Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair. Cell Cycle (2009) 2.31
Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res (2004) 2.28
Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell (2011) 2.23
Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23. Nat Genet (2002) 2.23
Magnitude of the dawn phenomenon and its impact on the overall glucose exposure in type 2 diabetes: is this of concern? Diabetes Care (2013) 2.17
β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell (2011) 2.17
Genome-wide association study in Han Chinese identifies four new susceptibility loci for coronary artery disease. Nat Genet (2012) 2.17
Bcl-2 and Bcl-xL play important roles in the crosstalk between autophagy and apoptosis. FEBS J (2010) 2.13
BAF180 is a critical regulator of p21 induction and a tumor suppressor mutated in breast cancer. Cancer Res (2008) 2.06
Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN(+/-) mice. Curr Biol (2005) 2.00
Proinvasion metastasis drivers in early-stage melanoma are oncogenes. Cancer Cell (2011) 1.99
Postprandial glucose regulation and diabetic complications. Arch Intern Med (2004) 1.97
Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome. Cancer Res (2003) 1.96
microRNA regulatory network inference identifies miR-34a as a novel regulator of TGF-β signaling in glioblastoma. Cancer Discov (2012) 1.94
Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res (2006) 1.91
Ascorbic acid enhances Tet-mediated 5-methylcytosine oxidation and promotes DNA demethylation in mammals. J Am Chem Soc (2013) 1.90
Genomic analysis of estrogen cascade reveals histone variant H2A.Z associated with breast cancer progression. Mol Syst Biol (2008) 1.89
High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res (2007) 1.88
A cytochrome C oxidase model catalyzes oxygen to water reduction under rate-limiting electron flux. Science (2007) 1.84
Analysis of Drosophila segmentation network identifies a JNK pathway factor overexpressed in kidney cancer. Science (2009) 1.83
DACH1 is a cell fate determination factor that inhibits cyclin D1 and breast tumor growth. Mol Cell Biol (2006) 1.80
Response of a KIT-positive extra-abdominal fibromatosis to imatinib mesylate and KIT genetic analysis. J Natl Cancer Inst (2006) 1.80
Automated quantitative analysis of tissue microarrays reveals an association between high Bcl-2 expression and improved outcome in melanoma. Cancer Res (2004) 1.80
Bax regulates primary necrosis through mitochondrial dynamics. Proc Natl Acad Sci U S A (2012) 1.80
Lifetime prevalence of mood and anxiety disorders in fragile X premutation carriers. J Clin Psychiatry (2010) 1.79
Self-harm in England: a tale of three cities. Multicentre study of self-harm. Soc Psychiatry Psychiatr Epidemiol (2007) 1.76
Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis. Clin Cancer Res (2003) 1.75
Rb function in extraembryonic lineages suppresses apoptosis in the CNS of Rb-deficient mice. Proc Natl Acad Sci U S A (2003) 1.74
Effects of berberine on glucose metabolism in vitro. Metabolism (2002) 1.74
The nuclear hormone receptor Coup-TFII is required for the initiation and early maintenance of Prox1 expression in lymphatic endothelial cells. Genes Dev (2010) 1.73
Utility of multispectral imaging for nuclear classification of routine clinical histopathology imagery. BMC Cell Biol (2007) 1.72
Optical recording of neuronal activity with a genetically-encoded calcium indicator in anesthetized and freely moving mice. Front Neural Circuits (2010) 1.71
Mapping segmental and sequence variations among laboratory mice using BAC array CGH. Genome Res (2005) 1.71
Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study. Cancer Res (2002) 1.69
Genome-wide array CGH analysis of murine neuroblastoma reveals distinct genomic aberrations which parallel those in human tumors. Cancer Res (2003) 1.67
Immunohistochemistry and quantitative analysis of protein expression. Arch Pathol Lab Med (2006) 1.65
Reciprocal regulation of Akt and Oct4 promotes the self-renewal and survival of embryonal carcinoma cells. Mol Cell (2012) 1.63
The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration. Cancer Res (2008) 1.63
Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanoma. Cancer Res (2007) 1.62
In situ identification of putative cancer stem cells by multiplexing ALDH1, CD44, and cytokeratin identifies breast cancer patients with poor prognosis. Am J Pathol (2010) 1.62
Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma. J Clin Oncol (2008) 1.61
Enhanced radical scavenging activity by antioxidant-functionalized gold nanoparticles: a novel inspiration for development of new artificial antioxidants. Free Radic Biol Med (2007) 1.59
Rhodocetin antagonizes stromal tumor invasion in vitro and other alpha2beta1 integrin-mediated cell functions. Matrix Biol (2002) 1.57
20q11.1 amplification in giant-cell tumor of bone: Array CGH, FISH, and association with outcome. Genes Chromosomes Cancer (2006) 1.56
Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clin Cancer Res (2011) 1.56
Pluripotency can be rapidly and efficiently induced in human amniotic fluid-derived cells. Hum Mol Genet (2009) 1.54
Standardization of estrogen receptor measurement in breast cancer suggests false-negative results are a function of threshold intensity rather than percentage of positive cells. J Clin Oncol (2011) 1.54
Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma. Neuro Oncol (2007) 1.53
Deletion of tetraspanin Cd151 results in decreased pathologic angiogenesis in vivo and in vitro. Blood (2006) 1.53
Reduced expression of PTEN correlates with breast cancer progression. Hum Pathol (2002) 1.53
Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience. Cancer (2005) 1.53